Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

Andrea R Shiakolas; Nicole Johnson; Kevin J Kramer; Naveenchandra Suryadevara; Daniel Wrapp; Sivakumar Periasamy; Kelsey A Pilewski; Nagarajan Raju; Rachel Nargi; Rachel E Sutton; Lauren Walker; Ian Setliff; James E Crowe Jr.; Alexander Bukreyev; Robert H Carnahan; Jason S McLellan; Ivelin S Georgiev.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-446813

Documentos relacionados

  1. Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking.
  2. Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
  3. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike.
  4. Development of COVID-19 therapies: Nonclinical testing considerations.
  5. Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests.
  6. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
  7. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence.
  8. Myeloid dysregulation and therapeutic intervention in COVID-19.
  9. Mechanisms of SARS-CoV-2 entry into cells.
  10. DeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2.